SWAV
10/15/26

ShockWave Medical (SWAV)

Thursday
8:11 AM
ThesisThe recent strategic partnerships and promising clinical trial results are enhancing investor confidence in ShockWave's growth trajectory.

Revenue Outlook

★ Analysts see FY2024 revenue reaching $922M — +26.2% growth in a single year.

Why Revenue Could Accelerate

  1. 01ShockWave's recent partnership with a major healthcare provider could accelerate IVL adoption, potentially increasing revenue by 30% over the next year.
  2. 02The company is exploring new indications for its IVL technology, which could expand its addressable market by an estimated $1.5B.
  3. 03Recent clinical trial results demonstrating improved patient outcomes could enhance the company's market position and lead to increased sales.
  4. 04Minimally invasive surgical techniques
  5. 05Growth in cardiovascular disease prevalence
  6. 06Adoption rates of IVL technology in hospitals and outpatient centers
  7. 07Regulatory approvals for new product indications
  8. 08Expansion into international markets, particularly Europe and Asia
FY2023 Snapshot
Revenue
$730M
NI Growth
-31.8%
EPS
$4.01

SWAV Chart

No chart data

My Notes

  • "Our innovative technology is gaining traction, and we are excited about the future opportunities in the cardiovascular market."
  • Moat: ShockWave's patented IVL technology provides a significant barrier to entry, protecting its market position.
  • growth - Investors are likely attracted to the high revenue growth potential and innovative technology.
  • Interest rates can affect the company's cost of capital and financing for expansion…
  • Watch on earnings: Adoption rate of IVL technology in new hospitals, Quarterly revenue growth, Gross margin trends.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $922M to $1.1B as shockwave's recent partnership with a major healthcare provider could accelerate ivl adoption.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.